← Back to Clinical Trials
Recruiting NCT06768580

NCT06768580 Effect of Oral Melatonin Versus Intraoperative Lidocaine Infusion on Incidence of Postoperative Delirium in Elderly Patients Undergoing Total Hip Arthroplasty

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06768580
Status Recruiting
Phase
Sponsor Tanta University
Condition Oral Melatonin
Study Type INTERVENTIONAL
Enrollment 135 participants
Start Date 2025-01-15
Primary Completion 2026-10-01

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
MelatoninLidocainePlacebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 135 participants in total. It began in 2025-01-15 with a primary completion date of 2026-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to assess the effect of oral melatonin versus intraoperative lidocaine infusion on incidence of postoperative delirium in elderly patients undergoing total hip arthroplasty under spinal anesthesia.

Eligibility Criteria

Inclusion Criteria: * Elderly patients aged \>65 years old undergoing unilateral total hip arthroplasty. * Patients with body mass index (BMI) (18-30) kg/m2. * American Society of Anesthesiologists (ASA) physical status I-III, scheduled to undergo unilateral total hip arthroplasty. Exclusion Criteria: * History of mental illness or scoring less than 8 using abbreviated mental test (AMT) before operation. * Obvious sinus bradycardia (heart rate of \<50 beats per minute) or other serious cardiovascular diseases. * Symptomatic cerebrovascular disease (such as previous stroke). * History of liver and kidney dysfunction. * Allergy to lidocaine or melatonin. * Metabolic disorders and fluid, electrolytes disturbances. * Alcohol dependence or drug abuse. * Redo surgery or infectious complications. * CNS medications (antipsychotics, anticonvulsants, antiparkinsonian, antidepressants). * History of deep vein thrombosis.

Contact & Investigator

Central Contact

Alshaimaa S Alasrag, Master

✉ alshaimaa.alasrag@med.tanta.edu.eg

📞 00201018940354

Frequently Asked Questions

Who can join the NCT06768580 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, studying Oral Melatonin. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06768580 currently recruiting?

Yes, NCT06768580 is actively recruiting participants. Contact the research team at alshaimaa.alasrag@med.tanta.edu.eg for enrollment information.

Where is the NCT06768580 trial being conducted?

This trial is being conducted at Tanta, Egypt.

Who is sponsoring the NCT06768580 clinical trial?

NCT06768580 is sponsored by Tanta University. The trial plans to enroll 135 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology